Connbe: The hydrochloride bromoso injection was evaluated for generic consistency

On 12 January, Connbe announced receipt of the Drug SupplementAl Application Approval issued by NMPA for ammonia hydrochloride injections, which are evaluated through generic consistency. the
hydrochloric acid bromoline injection is suitable for acute and chronic lung diseases with abnormal sputum secretion and poor sputum discharge, such as acute exacerbation of chronic bronchitis, wheezing bronchitis, sputum treatment of bronchial asthma, and preventive treatment of lung complications after surgery.
the variety has been included in the National Health Insurance Directory (2020 edition), category B drugs.
As of the date of disclosure of this announcement, the company and Sichuan Meida Kang Huakang Pharmaceutical Co., Ltd., Huahua Pharmaceutical Co., Ltd., Chengdu Bett Pharmaceutical Co., Ltd., Guangzhou One Red Pharmaceutical Co., Ltd., Shijiazhuang Four Pharmaceuticals Co., Ltd. and other 12 enterprises. according to the national enlarged version of
meters net, domestic sales of ammonia hydrochloride (including injections and oral solution forms) in 2019 were about 7.4 billion yuan, of which the sales of injections were about 6 billion yuan.
company's 2019 end-of-year sales (at the hospital's winning bid) of 0.93 billion yuan, accounting for about 1.55% of the injectable market share.
date of disclosure of this announcement, the Company has invested approximately RMB6.28 million (unaudited) in research and development for the consistent evaluation of the drug.